You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Refractory Multiple Myeloma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed and/or Refractory Multiple Myeloma Trial in Köln (BMS-986453, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Köln, Germany
    Local Institution - 0017
Dec 4, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Venetoclax)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • (no location specified)
Oct 30, 2023

Multiple Myeloma Trial (CM313 injection)

Not yet recruiting
  • Multiple Myeloma
  • CM313 injection
  • (no location specified)
Nov 6, 2023

Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma Trial in Boston (Elranatamab)

Not yet recruiting
  • Refractory Multiple Myeloma
  • +2 more
  • Boston, Massachusetts
  • +2 more
Nov 17, 2023

Multiple Myeloma Trial (AZD0305)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Oct 24, 2023

Relapsed or Refractory Multiple Myeloma Trial (Forimtamig, Carfilzomib, Daratumumab)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • (no location specified)
Sep 20, 2023

Relapsed and Refractory Multiple Myeloma Trial in Pittsburgh (Mezigdomide, Ixazomib, Dexamethasone)

Not yet recruiting
  • Relapsed and Refractory Multiple Myeloma
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 15, 2023

Relapsed/Refractory Multiple Myeloma Trial in Suzhou (ICI201)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Suzhou, Jiangsu, China
    First Affiliated Hospital, Soochow University
Jul 31, 2023

Multiple Myeloma Trial in Wollongong (IBI3003)

Not yet recruiting
  • Multiple Myeloma
  • Wollongong, New South Wales, Australia
    Wollongong Private Hospital
Oct 18, 2023

Multiple Myeloma Trial in Xuzhou (APRIL-BAFF-Bicephali CAR-T cells)

Recruiting
  • Multiple Myeloma
  • APRIL-BAFF-Bicephali CAR-T cells
  • Xuzhou, Jiangsu, China
    Kailin Xu
Nov 14, 2023

Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma Trial in Boston (Isatuximab, Belantamab mafodotin, Pomalidomide)

Not yet recruiting
  • Relapsed Cancer
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jun 19, 2023

Relapsed or Refractory Multiple Myeloma Trial in Tianjin (YTS104 Cells injection)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • YTS104 Cells injection
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jun 13, 2023

Multiple Myeloma Trial in Paris (Idecabtagene vicleucel, Not treated)

Active, not recruiting
  • Multiple Myeloma
  • Idecabtagene vicleucel
  • Not treated
  • Paris, France
    DESCAR-T Registry
Nov 27, 2023

Relapsed/Refractory Multiple Myeloma Trial in Benowa (ISB 2001)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • ISB 2001
  • Benowa, Queensland, Australia
    Pindara Private Hospital
May 18, 2023

Belantamab Mafodotin Care Patterns in Relapsed and/or Refractory

Not yet recruiting
  • Multiple Myeloma
  • Durham, North Carolina
    Duke University Medical Center
Aug 8, 2023

Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in Miami (Iberdomide, Carfilzomib, Daratumumab)

Not yet recruiting
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Miami, Florida
    University of Miami
May 31, 2023

Relapsed or Refractory Multiple Myeloma Trial in Tianjin (QLS32015)

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jun 24, 2023

Multiple Myeloma Trial in Houston (Belumosudil mesylate)

Not yet recruiting
  • Multiple Myeloma
  • Belumosudil mesylate
  • Houston, Texas
    M D Anderson Cancer Center
Oct 31, 2023

Relapsed/ Refractory Multiple Myeloma Trial (GC012F)

Not yet recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • GC012F
  • (no location specified)
Apr 28, 2023

Relapsed/Refractory Multiple Myeloma Trial in Suzhou (Mitoxantrone HCl liposome/Dexamethasone/daratumumab)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab
  • Suzhou, Jiangsu, China
    Second Affiliated Hospital of Soochow University
May 4, 2023

Relapsed and/or Refractory Multiple Myeloma, Plasma Cell Leukemia in Relapse Trial in Shanghai (Biological)

Recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Plasma Cell Leukemia in Relapse
  • Biological
  • Shanghai, Shanghai, China
    Shanghai Tongji Hospital
May 29, 2023

Relapsed or Refractory Multiple Myeloma Trial (Talquetamab)

Available
  • Relapsed or Refractory Multiple Myeloma
  • (no location specified)
Mar 6, 2023

Relapsed or Refractory Multiple Myeloma Trial (Cevostamab, Elranatamab, Tocilizumab)

Not yet recruiting
  • Relapsed or Refractory Multiple Myeloma
  • (no location specified)
Jun 22, 2023

Relapse/Refractory Multiple Myeloma Trial in Hangzhou (DeepTag-GPRC5D Targeted CAR T-cells)

Recruiting
  • Relapse/Refractory Multiple Myeloma
  • DeepTag-GPRC5D Targeted CAR T-cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Oct 10, 2023

Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Multiple Myeloma Trial in Changsha (BEBT-908 for

Completed
  • Relapsed or Refractory Non-Hodgkin's Lymphoma
  • Relapsed or Refractory Multiple Myeloma
  • BEBT-908 for injection
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Oct 9, 2023